Improved Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A novel multiplex single-cell genomic and immunophenotypic strategy leverages the sensitivity of MRD detection and distinguishes leukemic and preleukemic subpopulations.
Citing Articles
Zhang L, Deeb G, Deeb K, Vale C, Peker Barclift D, Papadantonakis N Cancers (Basel). 2024; 16(8).
PMID: 38672585 PMC: 11048433. DOI: 10.3390/cancers16081503.
The ferroptosis landscape in acute myeloid leukemia.
Ma Z, Ye W, Huang X, Li X, Li F, Lin X Aging (Albany NY). 2023; 15(22):13486-13503.
PMID: 38032290 PMC: 10713399. DOI: 10.18632/aging.205257.
References
1.
Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L
. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767.
PMC: 8718623.
DOI: 10.1182/blood.2021013626.
View
2.
Stasik S, Burkhard-Meier C, Kramer M, Middeke J, Oelschlaegel U, Sockel K
. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. Blood Adv. 2022; 6(11):3294-3303.
PMC: 9198930.
DOI: 10.1182/bloodadvances.2021006233.
View
3.
Robinson T, Bowman R, Persaud S, Liu Y, Neigenfind R, Gao Q
. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023; 9(38):eadg0488.
PMC: 10881057.
DOI: 10.1126/sciadv.adg0488.
View